HC Wainwright & Co. Reiterates Buy on Astria Therapeutics, Maintains $16 Price Target
Portfolio Pulse from Benzinga Newsdesk
HC Wainwright & Co. analyst Joseph Pantginis has reiterated a Buy rating for Astria Therapeutics (NASDAQ:ATXS) and maintained a price target of $16.
September 27, 2024 | 10:41 am
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
HC Wainwright & Co. has reiterated a Buy rating for Astria Therapeutics, maintaining a $16 price target, indicating confidence in the company's future performance.
The reiteration of a Buy rating and maintenance of a $16 price target by a reputable analyst suggests positive sentiment and potential upside for Astria Therapeutics' stock. This could lead to increased investor interest and a positive short-term impact on the stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100